INmune Bio Inc (INMB)
11.57
+0.44
(+3.95%)
USD |
NASDAQ |
May 03, 16:00
11.64
+0.06
(+0.56%)
After-Hours: 20:00
INmune Bio Cash from Operations (TTM): -11.98M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -11.98M |
September 30, 2023 | -14.27M |
June 30, 2023 | -13.38M |
March 31, 2023 | -14.96M |
December 31, 2022 | -22.69M |
September 30, 2022 | -26.77M |
June 30, 2022 | -31.33M |
March 31, 2022 | -32.28M |
December 31, 2021 | -28.50M |
September 30, 2021 | -21.12M |
June 30, 2021 | -16.89M |
Date | Value |
---|---|
March 31, 2021 | -13.00M |
December 31, 2020 | -8.943M |
September 30, 2020 | -6.984M |
June 30, 2020 | -5.232M |
March 31, 2020 | -5.032M |
December 31, 2019 | -5.385M |
September 30, 2019 | -5.414M |
June 30, 2019 | -3.918M |
March 31, 2019 | -3.118M |
December 31, 2018 | -2.059M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-32.28M
Minimum
Mar 2022
-3.918M
Maximum
Jun 2019
-15.16M
Average
-13.38M
Median
Jun 2023
Cash from Operations (TTM) Benchmarks
Biomarin Pharmaceutical Inc | 280.16M |
Sarepta Therapeutics Inc | -533.67M |
Dare Bioscience Inc | -38.86M |
Zevra Therapeutics Inc | -33.54M |
Kodiak Sciences Inc | -154.18M |